Previous 10 | Next 10 |
Government efforts to slow the spread of the SARS-CoV-2 virus have had severe negative consequences for the economy. While that includes obvious industries such as restaurants and air travel, the trickle of first-quarter 2020 earnings reported to date have demonstrated that most economic sectors...
Shares of genetic-testing company Invitae (NYSE: NVTA) rose over 13% today on an upbeat day for the stock market. The S&P 500 rose over 1.5% as investors cheered plans by some countries and U.S. states to soon begin reopening parts of their economies. While the broad econom...
SAN FRANCISCO , April 21, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its first quarter 2020 financial results on Tuesday, May 5, 2020 and will host a conference call and webcast that day at 4:30 ...
Partnership to reduce barriers to genetic diagnosis through sponsored testing for lysosomal storage diseases Initiative supports identification of patients with GM1 and GM2 gangliosidosis who are currently misdiagnosed or undiagnosed NEW YORK and BASEL, Switzerland, April 15, 20...
Shares of Invitae (NYSE: NVTA) rose nearly 12% today as the S&P 500 continued its seemingly improbable bounce back from March lows. There's a global pandemic. Tens of millions of Americans are out of work. Energy prices and demand have collapsed. The European Union as an entity might n...
When the stock market becomes ill, small-cap stocks often get the sickest of all. That's what's happened since the market swooned over worries about the impact of the COVID-19 pandemic. The iShares Russell 2000 ETF , weighted toward smaller stocks, is down 25% since the beginning of the year, c...
Organovo Calls Off Merger Agreement with Tarveda, Market Responds Positively Organovo Holdings, Inc. ( ONVO ) reported that it has terminated its merger agreement with Tarveda Therapeutics Inc. The decision was taken in a reconvened special meeting where the company stockholders voted agai...
Back in January, I detailed how genetics testing company Invitae ( NVTA ) still had much to prove . Management had just detailed a miss of 2019 revenue estimates, while large losses were leading to significant cash burn and tremendous ongoing dilution. A few months later, the stock has come d...
Invitae (NYSE: NVTA ) announces new tools to help healthcare providers who order genetic tests via telemedicine for women and couples early in pregnancy and for patients with cancer. More news on: Invitae Corporation, Healthcare stocks news, Stocks on the move, Read more ...
SAN FRANCISCO , April 7, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company today announced new tools to help obstetrician/gynecologists, oncologists, genetic counselors and other clinicians who order genetic tests via telemedicine for women and couples e...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...